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The Wilms Tumor Suppressor WT1 Encodes
a Transcriptional Activator of amphiregulin
at relatively low levels in blastemal cells, it appears to
be required both for their survival and their response to
inductive differentiation signals. A further role in renal
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Jenise Wong,1 Charles Paulding,1 development is evidenced by the very high, transient
expression of WT1 in differentiating glomeruli, a devel-Seung Kew Yoon,1,7 William Gerald,4
Jonathan D. Oliner,2,6 and Daniel A. Haber1,5 opmental stage that is not reached in WT1 null mice
(Pritchard-Jones et al., 1990). The characterization of1 Laboratory of Molecular Genetics
Massachusetts General Hospital Cancer Center WT1 as a transcriptional regulator suggests that identifi-
cation of its target genes may provide insight into itsand Harvard Medical School
Charlestown, Massachusetts 02129 function at various stages of normal development and
during tumorigenesis.2 Affymetrix
Santa Clara, California 95051 WT1 binds to both GC-rich and TC repeat elements
that are present in multiple promoters, leading to tran-3 Department of Physiology and Biophysics
Cornell Medical College scriptional repression in transient transfection assays
(see Rauscher, 1993). Based on the prototype WT1-New York, New York 10021
4 Department of Pathology responsive promoter, that of the immediate early gene
EGR1, WT1 has been thought to act by repressing ex-Memorial Sloan-Kettering Cancer Center
New York, New York 10021 pression of growth-inducing genes, including insulin-
like growth factor 2, insulin-like growth factor receptor,
platelet-derived growth factor A, epidermal growth fac-
tor receptor, transforming growth factor b, bcl2, c-myc,Summary
and others (reviewed in Rauscher, 1993). However, most
genes with WT1-responsive promoters are not physio-WT1 encodes a zinc finger transcription factor impli-
cated in kidney differentiation and tumorigenesis. In logically regulated by WT1 (Englert et al., 1995), and
recent studies have indicated that WT1 can either acti-reporter assays, WT1 represses transcription from
GC- and TC-rich promoters, but its physiological tar- vate or repress GC-rich promoter reporters, depending
upon experimental conditions (reviewed in Reddy andgets remain uncertain. We used hybridization to high-
density oligonucleotide arrays to search for native Licht, 1996). In addition, WT1 itself is encoded by differ-
ent splice forms, the most significant of which is thegenes whose expression is altered following inducible
expression of WT1. The major target of WT1 was am- variable insertion of three amino acids (KTS) between
zinc fingers 3 and 4 (Haber et al., 1991). WT1 proteinsphiregulin, a member of the epidermal growth factor
family. The WT1(2KTS) isoform binds directly to the lacking this insertion, WT1(2KTS), are present diffusely
in the nucleus and participate in regulation of transcrip-amphiregulin promoter, resulting in potent transcrip-
tional activation. The in vivo expression profile of am- tion, while the WT1(1KTS) variants are localized to dis-
crete subnuclear structures and may be associated withphiregulin during fetal kidney development mirrors the
highly specific pattern of WT1 itself, and recombinant some form of RNA processing (Larsson et al., 1995).
To identify potential physiological targets for WT1, weAmphiregulin stimulates epithelial branching in organ
cultures of embryonic mouse kidney. These observa- used U2OS osteosarcoma cells with tetracycline-regu-
lated inducible expression of the two isoforms andtions suggest a model for WT1 as a transcriptional
regulator during kidney differentiation. screened for altered expression profiles using oligonu-
cleotide microarrays representing 6800 human transcripts.
The major target gene of WT1(2KTS) identified was am-
Introduction phiregulin, encoding a growth and differentiating factor
of the epidermal growth factor (EGF) family (Plowman
WT1 was initially isolated as a gene that is inactivated et al., 1990). Amphiregulin is a ligand of the epidermal
in a subset of Wilms tumors and mutated in the germline growth factor receptor (EGFR) that is unique in exhibiting
of children with genetic predisposition to this kidney bifunctional properties, enhancing the proliferation of
cancer (reviewed in Hastie, 1994). Rather than generat- some epithelial cells while inhibiting that of many cancer
ing a tumor-prone phenotype, biallelic inactivation of cell lines (Shoyab et al., 1988). We demonstrate here
WT1 in the mouse results in the failure of kidney develop- that expression of amphiregulin is promptly and directly
ment, attributed to the widespread apoptosis of renal induced by WT1(2KTS). Immunohistochemistry and
blastemal cells, the stem cells that give rise to the renal RNA in situ hybridization studies reveal that WT1 and
nephron (Kreidberg et al., 1993). While WT1 is expressed amphiregulin share the same temporal and cell type±
specific expression pattern in the developing kidney.
5 To whom correspondence should be addressed (e-mail: haber@ Addition of recombinant Amphiregulin to embryonic kid-
helix.mgh.harvard.edu). ney rudiments stimulates epithelial differentiation in6 Present address: Amgen, One Amgen Center Drive, Thousand
vitro. These observations suggest that WT1 encodes aOaks, California 91320.
transcriptional activator and that its induction of amphi-7 Present address: Department of Internal Medicine, College of Medi-
cine, Catholic University of Korea, Seoul, South Korea. regulin may contribute to its role in renal differentiation.
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Table 1. Summary of Target Genes Induced by WT1(2KTS)a
Fold Induction
Accession by Oligonucleotide Fold Induction by
Number Description Array Hybridizationb Northern Blottingc
M30704 Amphiregulin 74.4 10
X51758 HSP70 6 5
U03106 p21CIP1 2.7 5
X65779 Acidic FGF 22.1 3
X05978 Cystatin A 59.4 Undetectabled
X58377 IL-11 18.8 Undetectabled
a Expression of the inducible murine WT1 cDNA itself is not detected by human oligonucleotide arrays.
b Average of two independent oligonucleotide array hybridization experiments.
c Quantitated by PhosphorImager.
d Northern blot analysis using 2 mg of poly A±selected RNA.
Results In contrast to WT1(2KTS), inducible expression of
WT1(1KTS) did not lead to significantly altered expres-
sion of any target genes, indicating that any transcrip-Analysis of Microarrayed Probes
We used high-density oligonucleotide microarrays to tional or posttranscriptional effects of this isoform are
likely to be restricted to transcripts that are not repre-search for endogenous genes whose expression is al-
tered following inducible expression of WT1 in U2OS sented on the microarrays. No significant differences in
the expression profile of control cell lines expressinghuman osteosarcoma cells. In these cells with tightly
regulated, tetracycline-repressible induction of WT1 only the tetracycline-regulated transactivator were ob-
served following withdrawal of tetracycline (data notsplice variants, expression of WT1(2KTS) at levels com-
parable to those observed in developing glomeruli leads shown).
to apoptosis after 48 hr, an effect that is not observed
with the WT1(1KTS) splice variant (Englert et al., 1995). Induction of amphiregulin by WT1(2KTS)
Given the magnitude of amphiregulin mRNA inductionTo identify direct transcriptional targets, cells in mid±log
phase were grown in the absence of tetracycline for by WT1(2KTS), we sought to determine whether it might
constitute a direct transcriptional target. As predicted11 hr, at which time poly(A)1 RNA was isolated and
used to interrogate oligonucleotide arrays representing by chip hybridization experiments, Northern blotting
confirmed that induction of amphiregulin was specific6800 known genes and expressed sequence tags (EST)
(Lockhart et al., 1996). Expression profiles in cells with to the WT1(2KTS) splice variant, thought to encode the
transcriptionally active form of WT1 (Figure 1A). Theinducible WT1(2KTS) were compared to those express-
ing comparable levels of WT1(1KTS) and cells trans- time course of amphiregulin mRNA induction following
expression of WT1(2KTS) in U2OS cells was coinciden-fected with the empty vector. Northern blots were used
to validate all expression changes greater than 5-fold tal with that of WT1 itself, readily detectable within 3
hr of tetracycline withdrawal (Figure 1B). Readdition ofidentified by array hybridization experiments.
A summary of expression profile upon inducible ex- tetracycline and suppression of WT1 expression re-
sulted in concomitant decrease in amphiregulin expres-pression of WT1(2KTS) is shown in Table 1. Of 12 genes
and ESTs found to be induced by microarray hybridiza- sion (data not shown). To determine whether amphireg-
ulin is induced by WT1 in appropriate cell types,tion, 4 were confirmed as induced by Northern blotting.
Most striking was the potent (74-fold) induction of am- specifically cells of embryonic kidney origin, we estab-
lished tetracycline-regulated inducible expression ofphiregulin mRNA, confirmed as 10-fold increased ex-
pression by Northern blotting (Figure 1A). Lower levels WT1 isoforms in RSTEM cells, immortalized kidney cells
isolated from day 12.5 rat embryos. In these cells, en-of induction were observed for Hsp70 and p21Cip1 tran-
scripts, which are known to be induced following WT1 dogenous WT1 mRNA is detectable at baseline, and
5- to 10-fold induction of WT1 isoforms is observedexpression in these cells (Englert et al., 1997; Mahes-
waran et al., 1998). Acidic fibroblast growth factor mRNA following withdrawal of tetracycline. Induction of endog-
enous rat amphiregulin mRNA was observed 6 hr follow-was also induced more modestly, following expression
of WT1(2KTS). Two additional targets identified as sig- ing expression of WT1(2KTS) but not WT1(1KTS) (Fig-
ure 1C). Presence or absence of another alternativenificantly induced by microarray hybridization were ex-
pressed at levels below detection by Northern blotting splice, encoded by exon 5 of WT1 (Haber et al., 1991),
did not significantly alter induction of amphiregulin byanalysis of poly(A)1-selected RNA and hence could not
be confirmed (see Table 1). Six other potential targets WT1(2KTS) (data not shown).
identified by microarray hybridization were not found to
be induced by Northern blotting analysis using either Direct Activation of the amphiregulin Promoter
by WT1(2KTS)total cellular RNA or poly(A)1-selected RNA (data not
shown), a discrepancy most likely attributable to inter- To identify a potential cis-acting, WT1-responsive site
within the human amphiregulin promoter, we identifiedreplicate biological variation. Remarkably, no target
genes were found to be reproducibly repressed follow- a bacterial artificial chromosome (BAC) containing the
known upstream regulatory sequences (Plowman et al.,ing expression of WT1(2KTS).
Induction of amphiregulin by WT1
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2267 to 2274 nt) displayed some level of WT1(2KTS)-
dependent activation. However, in contrast to the WRE,
the CRE site did not display direct WT1 binding, sug-
gesting that it may contribute indirectly to WT1-medi-
ated activation (see below). In the presence of the WRE,
deletion of the CRE site did not diminish activation of
the amphiregulin promoter by WT1(2KTS), indicating
that this response element is not synergistic with the
WRE (Figure 2B; pGL2-B-DCRE).
To establish direct binding of WT1(2KTS) to the am-
phiregulin promoter, we first undertook DNase I footprint
analysis using a genomic fragment of 300 bp, upstream
of the transcriptional start site. Incubation with recombi-
nant GST-WT1 protein, containing either the (2KTS) or
(1KTS) zinc finger domains, revealed protection by
WT1(2KTS) of only a 16 bp sequence, 59-CCCGGCCGT
GGGTGGA-39 (antisense strand), between 2294 and 2278
nt (Figure 2C). The location of this potential WT1(2KTS)-
binding site was within the 60 bp minimal WT1-respon-
sive element defined above. Neither the CRE site nor other
GC-rich sequences that fit the WT1 consensus sequence
were protected by WT1(2KTS), and WT1(1KTS) failed
to protect any sequences within the amphiregulin pro-
moter from DNase I cleavage. To confirm the identifica-
tion of this potential WT1(2KTS) binding sequence, elec-
trophoretic mobility shift assays (EMSA) were used to
demonstrate binding of WT1(2KTS), but not WT1(1KTS),
to the 60 bp (2328 to 2275 nt) promoter fragment (Figure
2D). Further dissection of this fragment indicated that
the WT1(2KTS)-binding site was between positions
2315 and 2275 nt, overlapping precisely with that iden-
tified by DNase I footprint analysis.
Characterization of Native WT1(2KTS)
Binding SequenceFigure 1. Induction of amphiregulin mRNA by WT1(2KTS)
Consensus DNA recognition sequences for WT1(2KTS),(A) Northern blot analysis of U2OS cells with tetracycline-regulated
expression of WT1(2KTS), WT1(1KTS), or vector, following growth containing either GC-rich or TC repeats, have been
in the presence or absence (11 hr) of tetracycline. Blots were hybrid- derived from analysis of WT1-responsive promoters
ized with probes for WT1, amphiregulin, and GAPDH (loading (Rauscher et al., 1990; Wang et al., 1993). However, since
control). the regulation of these promoter reporters in transient
(B) Kinetics of WT1 and amphiregulin induction following tetracy-
transfection assays has not been well correlated withcline withdrawal. Total RNA was isolated following growth in the
induction of the endogenous promoters by WT1(2KTS),presence of tetracycline and 0, 3, 6, or 9 hr following drug with-
drawal. we sought to define the WRE within a gene that appears
(C) Northern blot analysis of embryonic rat kidney RSTEM cells with to be a physiological target of WT1. The protected 16 nt
tetracycline-regulated expression of WT1(2KTS) and WT1(1KTS). sequence from the amphiregulin promoter was therefore
Total RNA was isolated 6 hr after tetracycline withdrawal and probed analyzed by mutagenesis and EMSA. For optimal align-
for WT1, amphiregulin, and GAPDH.
ment with other potential WT1 binding sequences, the
WRE is shown in the antisense orientation (Figure 3A).
The five 59-terminal nucleotides and the 39-terminal
1990), which were then inserted into the promoterless adenosine were not required for WT1(2KTS) binding.
luciferase reporter plasmid pGL2. Activation of the re- The remaining 10 nt sequence from the amphiregulin
porter by WT1 isoforms was tested using transient co- promoter (defined here as WRE) is most similar to the
transfection into NIH3T3 cells, which express undetect- ªWTEº motif 59-GCGTGGGAGT-39, a high-affinity WT1-
able levels of endogenous WT1. A genomic fragment binding site identified by in vitro selection assay that
containing the known amphiregulin promoter (287 to displays higher binding affinity for WT1(2KTS) than ei-
2850 nt; pGL2-A) was activated 20- to 25-fold by ther the GC-rich EGR1 consensus or the TC repeat sites
WT1(2KTS) but not WT1(1KTS) (Figures 2A and 2B). derived from WT1-responsive promoter reporters (Na-
No further activation was observed by inclusion of an kagama et al., 1995). The antisense strand of the WRE,
additional 1 kb of upstream sequence derived from the 59-CCGTGGGTGG-39, differs at only three positions (un-
BAC (data not shown). Progressive deletion constructs derlined) from the predicted optimal WTE motif.
mapped the major WT1-responsive element (WRE) to To determine the relative contribution of each of the
60 nt, between positions 2328 and 2275 (Figure 2B). ten nucleotides within the WRE, mutations were intro-
duced at every position and analyzed by EMSA, usingWe also observed that the CRE site (Montminy, 1997;
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Figure 2. Identification of WT1-Responsive Element within amphiregulin Promoter
(A) Schematic representation of the human amphiregulin promoter indicating the relative positions of the TATA box (2238 to 2233), CRE site
(2274 to 2267), and adjacent WRE (2292 to 2283; see below). Nucleotide numbers refer to promoter sequence (Plowman et al., 1990). Three
luciferase reporter plasmids (A±C) generated in the promoterless backbone pGL2 are shown, representing nested deletions.
(B) Activation of the amphiregulin promoter by WT1(2KTS). Luciferase activity, relative to vector-transfected cells, was measured in NIH3T3
fibroblasts 48 hr following cotransfection of reporter constructs (2 mg) and either WT1(2KTS) or WT1(1KTS) expression plasmids (5 mg).
Reporter plasmids are the nested deletion contructs pGL2-A-C, in addition to the respective constructs with deletion of the CRE site (DCRE),
to demonstrate the small and nonsynergistic effect of this site adjacent to the WRE. Transfection efficiency was standardized using a
cotransfected reporter (human growth hormone), and equal amounts of CMV promoter were present in each transfection; standard deviations
were derived from three independent experiments.
(C) DNase I footprint analysis of a 300 bp fragment of the amphiregulin promoter (nucleotides 2385 to 287). The end-labeled fragment was
incubated with 0, 20, or 80 ml of GST-WT1(2KTS) or GST-WT1(1KTS), followed by partial DNase I digestion. The 16 bp region protected by
80 ml of WT1(2KTS) is indicated by the black box (2294 to 2278); the CRE site is represented by a white box.
(D) EMSA analysis of amphiregulin promoter fragments following incubation with the zinc finger domains of either WT1(2KTS) or WT1(1KTS).
Overlapping genomic probes were generated by restriction digestion of the pGL2-B promoter fragment using enzyme pairs XhoI/AatII and
NarI/AatII, whose cleavage sites are indicated. The black box indicates the DNase I±protected region. End-labeled probes (free probe designated
P) were incubated with 200 ng of the respective GST fusion proteins. The positions of unbound (bracket) and complexed probe (arrow) are
shown.
both quantitative measurement of protein complex for- or T10 resulted in moderate (2- to 4-fold) increase in
WT1(2KTS) binding (Figure 3B; G10 to T substitution ismation and oligonucleotide competition experiments.
Substitution of C2, G3, G5, G6, and G7 to thymidine or shown in Figure 3A). In competition experiments, the
single substitution of the WRE T8 to the correspondingsubstitution of T4 to adenosine resulted in either com-
plete or significant loss of WT1(2KTS) binding (Figure A8 from WTE was sufficient to increase its binding affinity
for WT1(2KTS) to that of the WTE consensus (Figure 3C).3B). In contrast, replacement of either C1 or G9 with
thymidine had minimal effect. At positions where the To confirm that the WRE is responsible for tran-
scriptional activation of the amphiregulin promoter byWRE sequence differs from the WTE consensus, such
as the T8 and G10, substitution with the WTE-derived A8 WT1(2KTS), the mutant WRE, encoding T4, G6, and G7
Induction of amphiregulin by WT1
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Figure 3. Characterization of WT1-Responsive Element within the amphiregulin Promoter
(A) Minimal WRE (10 nucleotides), identified by EMSA, following thymidine substitution of the 59 and 39 terminal residues of the 16 nucleotide
fragment protected by DNase I footprint analysis (shown at top in antisense orientation). Complex formation by WT1(2KTS), but not WT1(1KTS),
is shown for the full DNase I±protected fragment (at right). Thymidine-substituted residues are indicated in boxes (sub), free probe is denoted
with a bracket, and the position of the protein complex is indicated with an arrow. The G→T change at the 39 end of WRE (as), which results
in increased binding by WT1(2KTS), represents the tenth position of the WRE (see below).
(B) Identification of essential residues within the WRE. The ten nucleotides of the Amphiregulin antisense WRE (as) are aligned with the ten
nucleotides of the sense WTE (s), the optimized in vitro binding sequence for WT1(2KTS) (Nakagama et al., 1995). Identical residues are
marked by a vertical line. EMSA analysis of WT1(2KTS), WT1(1KTS), or free probe (P) for the WRE (left) is compared with probes containing
a substitution at each nucleotide constituting the WRE. All nonthymidine residues were substituted to thymidine; thymidine residues were
substituted to adenosine. Numerical positions correspond to the 59 to 39 WRE (as) and WTE (s) sequences. Equal amounts of probe and WT1
protein were added in all cases; both parts of the panel were derived from the same experiment. Migration of free probe (bracket) and the
protein complex (arrow) are shown.
(C) Relative binding affinity of WT1(2KTS) for WRE, WTE, and substituted WRE (G6T, G5T, and T8A), assessed by competition of unlabeled
probes (indicated above each lane; 300- or 600-fold molar excess) with the end-labeled WRE probe. Incubation of WT1(2KTS) or WT1(1KTS)
with WRE, in the absence of competing probes, is shown at left. Migration of the protein complex is denoted by arrow.
(D) Effect of mutant WRE on transcriptional activation of the amphiregulin promoter by WT1(2KTS). Luciferase activity, relative to vector
transfection, following cotransfection of NIH3T3 cells with CMV-driven WT1(2KTS) or WT1(1KTS) and the following reporters: full-length
amphiregulin promoter (pGL2-A), full-length promoter containing point mutations disrupting the WRE (adenosine substitutions at positions
T4, G6, and G7; pGL2-A-mWRE), and a truncated promoter containing only the CRE site and TATA box (pGL2-C). Results are shown for two
independent transfection experiments.
substitutions to adenosine, was engineered into the full- to the presence of the CRE site, which displays modest
activation by WT1 in the absence of direct DNA bindinglength pGL2-A luciferase reporter construct. This alter-
ation reduced WT1-mediated transactivation to the (data not shown). Combining our results and the work
of Nakagama et al. (1995), we can therefore derive a 10baseline observed with the truncated reporter pGL2-C
(Figure 3D). The residual activity of this reporter is due bp consensus WT1(2KTS)-binding site that appears to
Cell
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Figure 4. Colocalization of WT1 and amphi-
regulin Expression in Structures of the Differ-
entiating Kidney
Immunohistochemical analysis of (A) WT1
and (B) Amphiregulin expression in differenti-
ating structures within the nephrogenic zone
of the developing human kidney (18 weeks).
Blastema (B) denotes the condensed mesen-
chymal cells located in the outermost subcor-
tical region and shows low levels of expres-
sion. Developing glomeruli (DG), with peak
WT1 and Amphiregulin expression, are lo-
cated centrally to the blastemal layer. Mature
glomeruli (MG) are in the most central region
of the nephrogenic zone. Insets show strong
expression of both WT1 and Amphiregulin in
the podocyte layer of developing glomeruli.
RNA in situ analysis of (C) WT1 and (D) amphi-
regulin expression in sections of the 18-week
human kidney. Blastema, developing, and
mature glomeruli are identified as above.
Specificity of the hybridization was confirmed
through the use of sense probes (not shown).
Insets show high magnification to illustrate
increased expression in condensed blastema
for both WT1 and amphiregulin.
be required for transcriptional activation in vivo: 59-(C/G/ differentiating glomeruli, demonstrated both by immu-
nohistochemistry (Figure 4A) and by RNA in situ hybrid-T)CGTGGG(A/t)(G/t)(T/g)-39, where nucleotides within the
parentheses indicate tolerable changes and small letters ization (Figure 4C). Also in accordance with previous
results, antibody staining shows persistent low levelsrepresent changes that result in suboptimal binding.
of WT1 protein in the podocytes of mature glomeruli,
but WT1 RNA levels are apparently below the level ofCoexpression of WT1 and amphiregulin in Developing
Structures of the Fetal Kidney detection by in situ hybridization. Remarkably, analysis
of amphiregulin expression was virtually superimpos-The critical role of WT1 during kidney development is
reflected in its highly restricted pattern of expression able on that of WT1. Both immunohistochemistry (Figure
4B) and RNA in situ hybridization (Figure 4D) demon-(Pritchard-Jones et al., 1990). To determine whether
induction of amphiregulin by WT1 in cultured cells re- strated high levels of expression in condensed blaste-
mal cells, S-shaped bodies, and podocytes of differenti-flects a potential physiologically significant interaction,
we therefore compared their expression in developing ating glomeruli. Low levels of amphiregulin mRNA were
also noted in maturing glomeruli by RNA in situ hybrid-structures of the fetal kidney. The 18-week human kid-
ney displays the sequential stages of glomerular differ- ization. Thus, the precise temporal and spatial specific-
ity of WT1 and amphiregulin expression in the fetal kid-entiation in an ordered progression from the outermost
undifferentiated blastemal cells in the subcortical re- ney are consistent with a developmentally regulated
differentiation pathway.gion, which condense to form the epithelium of so-called
ªS-shapedº bodies, evolving into differentiating glomer-
uli, and on to the more centrally located mature glomeruli Induction of Ureteric Bud Branching in Kidney
Organ Cultures by Amphiregulin(Davies, 1996). Consistent with previous results (Pritchard-
Jones et al., 1990), high levels of WT1 expression are The progression of developmental structures that leads
to renal organogenesis is complex, reflecting early in-present in the condensed blastema, S-shaped bodies, and
Induction of amphiregulin by WT1
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bud branching of nearly 2-fold compared with untreated
controls (Figure 5). The magnitude and dose respon-
siveness of this effect in this highly reproducible biologi-
cal assay is highly significant and comparable to that
observed following addition of exogenous glial cell±
derived neurotrophic growth factor (GDNF), a mesen-
chymal growth factor known to be a primary mediator
of ureteric bud invasion and branching (Pepicelli et
al., 1997).
Discussion
We have used expression profile analysis to search for
cellular targets of WT1, a transcription factor implicated
in renal development and malignant transformation. By
combining tightly regulated inducible expression in a
cell culture model with hybridization of cellular mRNA
to high-density microarrays, we were able to screen
6800 genes and ESTs, identifying amphiregulin as a
major WT1 target gene. A potentially important physio-
logical pathway is suggested by the precise spatial and
temporal coexpression of these two genes in condensed
renal blastemal cells and differentiating glomeruli and
the stimulation by Amphiregulin of renal tubular differen-
tiation in vitro. The direct binding of WT1(2KTS) to a
Figure 5. Induction of Ureteric Bud Branching by Recombinant Am- high-affinity site within the amphiregulin promoter and
phiregulin in Cultured Mouse Metanephric Kidney Rudiments
its potent activation of this promoter suggest that WT1
Staining of the ureteric bud network (FITC-Dolichos Bifloris stain)
may function as a transcriptional activator of specificin microdissected mouse metanephric kidney rudiments, cultured
promoters rather than as a global repressor of GC- andin the absence or presence of 20 ng/ml purified Amphiregulin. A
TC-rich promoters. The ability to derive a potential tis-representative section is shown in upper panel. Dose dependence
of the effect of Amphiregulin (0, 5, 20, or 100 ng/ml) on branching sue-specific physiological pathway using DNA array±
of single ureteric bud tubules was quantitated (lower panel). For based expression profile analysis demonstrates an ef-
each culture condition, a minimum of 15 rudiments were analyzed fective approach for identifying targets of transcriptional
and the number of terminal branches recorded. Significant differ-
regulators.ences in ureteric bud branching were detected at Amphiregulin con-
centrations greater than 5 ng/ml (Student t-test; p , 0.001).
Expression Profiling to Define
Transcriptional Targetsductive signals defining mesenchymal and epithelial cell
fates as well as subsequent stimuli leading to cellular The difficulty in defining physiological downstream tar-
get genes of transcription factors has long been a majordifferentiation and proliferation (Davies, 1996). The ex-
pression pattern of both WT1 and amphiregulin suggests impediment to discerning their biological function. To
date, unbiased screening approaches have includedpotential contributions to both of these developmental
stages. However, the failure of kidney development in subtractive hybridization and SAGE (El-Deiry et al., 1993;
Velculescu et al., 1995). Both of these methods are tech-WT1 null mice reflects the earliest stage of renal differen-
tiation, where low levels of WT1 expression in blastemal nically challenging, and the ability to screen DNA mi-
croarrays is likely to provide a high throughput andcells appear to be essential for the reciprocal induction
signals between ureteric bud and undifferentiated mes- broadly applicable approach. Such arrays have been
used to monitor differences in expression profiles fol-enchyme and for survival of the mesenchymal blastema
itself (Kreidberg et al., 1993). To examine the potential lowing perturbation of the cell cycle in yeast (Wodicka
et al., 1997; Cho et al., 1998) or serum stimulation incontribution of Amphiregulin to this process, we used
a short-term in vitro organ culture assay that has been mammalian cells (Iyer et al., 1999). These manipulations
lead to global changes in cellular physiology, reflectedused to model early stages of renal differentiation
(Saxen, 1987; Qiao et al., 1999). Undifferentiated meta- in a large number of differences in expressed transcripts
between samples. In contrast, screening for specificnephric kidney rudiments were isolated from day 11.5
mouse embryos, a stage of development that allows transcriptional targets following inducible expression of
a transcription factor is likely to lead to a small numberdissection of the mesenchyme surrounding a single ure-
teric bud branch. These were plated onto nitrocellulose of expression changes, posing a challenge for both sen-
sitivity and specificity. While only z7% of all potentialfilters and allowed to differentiate in vitro in the presence
or absence of recombinant Amphiregulin. As expected, human transcripts were interrogated in our screen for
WT1 targets, the sensitivity of our analysis is supportedkidney rudiments developed a network of branching tu-
bules associated with condensation of mesenchymal by the correct identification of two weakly induced tran-
scripts, Hsp70 and p21Cip1, the only two genes previouslycells. Addition of purified Amphiregulin to organ cultures
demonstrated a dose-dependent increase in ureteric known to be induced by WT1 expression in these cells
Cell
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(Englert et al., 1997; Maheswaran et al., 1998). The speci- cells (data not shown). Inducible expression of WT1 also
does not lead to altered expression of WNT4, BMP7, orficity of microarray-based screening results depends to
a great extent on experimental conditions and criteria PAX2 (data not shown), suggesting that other signaling
molecules are likely to mediate the effects of WT1 onset to identify potential targets (Lockhart et al., 1996;
Harkin et al., 1999). Thus, 4 of 12 potential targets identi- renal development.
Amphiregulin is unlikely to constitute the sole WT1fied by chip hybridization experiments were confirmed
by Northern blotting, with the discrepancies explained target gene required for its effect on ureteric branching
and blastemal cell survival. Tissues showing develop-either by differences in detection of the hybridization
signal or variations in experimental conditions. Thus, mentally regulated expression of amphiregulin, includ-
ing lung and kidney, have no gross developmental de-of 6800 known genes and ESTs interrogated by chip
hybridization, amphiregulin was the major target gene fects in amphiregulin null mice, pointing to the extensive
functional redundancy in both ligands and receptors ofinduced by WT1.
the EGF family (Luetteke et al., 1999). Nonetheless, the
EGF pathway is likely to play an important role in renalPotential Role of Amphiregulin
differentiation: the EGF receptor is expressed both inin Renal Differentiation
blastemal cells and in the ureteric bud, consistent withThe identification of amphiregulin as a WT1 target was
a role in both mesenchymal±ureteric interactions andmade possible by the use of expression profile analysis,
proliferation of the mesenchyme itself, and exogenoususing tightly regulated inducible gene expression in a
administration of EGF suppresses developmentally reg-heterologous cell type. However, the physiological rele-
ulated renal apoptosis (Fisher et al., 1989; Coles et al.,vance of amphiregulin induction by WT1 is supported
1993). The direct induction of amphiregulin by WT1,by a number of observations. First, endogenous amphi-
together with its specific expression pattern in the devel-regulin is induced by WT1(2KTS) in RSTEM cells, which
oping kidney and its ability to induce ureteric budare immortalized from rat embryonic kidney at a time of
branching in embryonic organ culture, thus suggestsearly organ differentiation. Second, the precise temporal
that Amphiregulin plays an important, if not essential,and spatial pattern of WT1 and amphiregulin expression
role in early renal differentiation.in the developing human kidney is virtually superimpos-
The function of Amphiregulin in later stages of glomer-able. Third, recombinant Amphiregulin demonstrates
ular differentiation is not readily modeled in vitro. It ispotent induction of renal tubular branching in an embry-
presumably at this later stage of organogenesis thatonic organ culture model. This in vitro model offers only
WT1 inactivation leads to the development of Wilmsan approximation of some of the complex early events
tumor. The function of WT1 as a tumor suppressor isin renal differentiation, and it does not reproduce the
likely to involve loss of a differentiation signal in a pluri-later developmental stages where both WT1 and amphi-
potent blastemal stem cell, resulting in its failure to ter-regulin expression peak. Nonetheless, it provides strong
minally differentiate, and leading to its continued prolif-evidence that induction by WT1 of this secreted growth
eration and eventual malignant transformation (seefactor is likely to have an important effect on the prolifer-
Hastie, 1994). It is interesting to note that Amphiregulin isation and differentiation of embryonic kidney cells.
a weak mitogen for some epithelial cells, while it inhibitsDevelopment of the metanephric kidney is initiated by
proliferation in many cancer cell lines (Shoyab et al.,signals from the metanephric mesenchyme that induce
1988). Cell lines in which the antiproliferative effect ofinvasion of the adjacent ureteric bud, followed by recip-
WT1 has best been demonstrated, the osteosarcomarocal inductive interactions between mesenchyme and
cell lines U2OS and Saos-2 (Englert et al., 1995) andureter (Saxen, 1987). These signals lead the metanephric
the Wilms tumor cell line RM1 (Haber et al., 1993), areblastema to condense and differentiate to form glomer-
potently growth suppressed by expression of amphi-uli and associated tubules, while the ureteric bud in-
regulin (data not shown). Amphiregulin mRNA was notvades and branches into the mesenchyme, giving rise
detectable by Northern blotting or RNA in situ hybridiza-to the collecting system. Critical molecules involved in
tion in a panel of 12 primary Wilms tumor specimensthese processes have been identified by their expres-
lacking WT1 mutations, but no mutations in amphiregulinsion profile, their effect in embryonic kidney organ cul-
itself were detected in these tumors. The mechanism ofture models, and the consequences of their inactivation
WT1-mediated tumor suppression and the potentialin the mouse. In addition to WT1, important roles in renal
contribution of amphiregulin to this effect thereforedifferentiation have been noted for genes encoding the
await the development of models of Wilms tumori-growth factors WNT4 and BMP7 and the transcription
genesis.factor PAX2 (reviewed in Vainio and Muller, 1997). How-
ever, the earliest signal appears to result from mesen-
chymal secretion of GDNF, which binds to its corecep- Transcriptional Activation of amphiregulin by WT1
WT1 has been described as a transcriptional repressortors, c-ret and GDNF-Ra, expressed in the ureteric bud.
Inactivation of either ligand or receptors leads to failure based on its ability to repress GC- and TC-rich promot-
ers in transient transfection assays (see Rauscher,of the inductive process and renal agenesis (Moore et
al., 1996; Pichel et al., 1996; Sanchez et al., 1996). Inacti- 1993). However, few genes whose promoters contain
these WT1-responsive sequences show regulation ofvation of WT1 results in a similar phenotype, although
mesenchymal synthesis of GDNF is unaltered by inacti- the native transcript following expression of WT1. This
discrepancy presumably results from the loss of speci-vation of WT1 (Donovan et al., 1999) and we did not
detect altered expression of GDNF following inducible ficity associated with transient overexpression of both
WT1 and reporter constructs, as well as the importanceexpression of WT1 in the rat embryonic kidney RSTEM
Induction of amphiregulin by WT1
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of stoichiometric interactions with other transcriptional N-terminal domain of WT1 required for its association
regulators and chromatin structure, which are not well with Hsp70 is essential for both suppression of colony
replicated in these assays (reviewed in Kadonaga, 1998). formation and induction of p21Cip1 but not for transcrip-
Even in transient assays, the use of different expression tional repression of GC- and TC-rich reporter constructs
plasmids and variations in cellular and promoter context (Maheswaran et al., 1998). Consistent with these obser-
have been associated with both transcriptional activa- vations, our screen of DNA microarrays identified a tar-
tion and repression by WT1 (see Reddy and Licht, 1996). get gene whose expression is induced by WT1 but failed
A detailed analysis of the WT1-binding site in the hu- to confirm any targets whose expression were re-
man amphiregulin gene promoter (WRE) revealed a strik- pressed. Taken together, these observations suggest
ing similarity to WTE, a high-affinity WT1 binding sequence that WT1 may encode a transcriptional activator of spe-
derived by whole-genome PCR but not previously found cific genes implicated in cellular differentiation.
in a WT1-responsive promoter (Nakagama et al., 1995).
In contrast, the WRE shows significant divergence from Experimental Procedures
the GC-rich and TC repeat consensus sequences pres-
Expression Profiling Using Oligonucleotide Arraysent in multiple promoters that are repressed by WT1.
U2OS cells with tetracycline-regulated, inducible expression ofThese differences may explain in part the distinction
WT1(2KTS) (UB27 cells), WT1(1KTS) (UD28 cells), or vector alonebetween physiological targets of WT1 and promoters
(UV9 cells) have been described previously (Englert et al., 1995). In
that are only affected by WT1 in the context of promoter two independent experiments, poly(A)1 RNA was isolated from
reporter studies. Identification of other endogenous tar- these cells 11 hr after withdrawal of tetracycline. The RNA was
get genes of WT1 will determine whether the WRE/WTE amplified, labeled, and hybridized to oligonucleotide arrays repre-
senting 6800 transcripts for known genes and ESTs, as describedmotif is indeed the critical sequence for in vivo binding
(Lockhart et al., 1996; Wodicka et al., 1997). Criteria used for quanti-by WT1(2KTS). In this regard, it is interesting to note
tative analysis of array hybridization results included a .5-foldthat another WT1 target gene identified in the microarray
change in signal intensity and reproducibility in two experiments.
screen, aFGF, also contains a WRE/WTE±like sequence
in its promoter. Luciferase Reporter Assays
It is likely that additional sequences present in cis CMV-driven WT1 constructs have been described elsewhere (Eng-
within WT1-responsive promoters may also be impor- lert et al., 1995). Fragments of the amphiregulin promoter were PCR
amplified from human genomic DNA (Plowman et al., 1990) andtant in defining induction by WT1. Activation of the MuÈ l-
inserted into the promoterless reporter pGL2 (Promega) (constructslerian inhibiting substance (MIS) promoter by the orphan
pGL2-A, -B, and -C are shown in Figure 2A). Substitutions in thereceptor SF1 is greatly enhanced by coexpression of
WT1-binding site of pGL2-A were introduced by PCR to change theWT1(2KTS), although WT1 does not bind directly to
thymidine at WRE position 4 and the guanidines at positions 6 and
the MIS promoter, nor does it form a stable protein 7 to adenosine (construct pGL2-A-mWRE). Deletion of the CRE site
interaction with SF1 (Nachtigal et al., 1998). Such coop- in reporter constructs was achieved by digestion with AatII and
erative interactions may also contribute to the activation treatment with T4 DNA polymerase. For luciferase reporter assays,
NIH3T3 cells were transfected with equal amounts of 5 mg of CMV-of amphiregulin by WT1. We note the presence of a CRE
driven WT1 (1 or 2KTS) or the empty vector, along with 2 mg of thesite adjacent to the WRE in the amphiregulin promoter,
relevant reporter construct by the calcium phosphate precipitationwhich is activated following WT1 expression but is not
method. A cotransfected plasmid encoding human growth hormone
bound directly by WT1. CRE sites are frequently located (HGH; 1 mg) was used to normalize for transfection efficiency.
adjacent to other regulatory sequences, such as Sp1
sites, and may modulate promoter responsiveness, pre- Electrophoretic Mobility Shift Assays
sumably through recruitment of CREB-binding protein Given the insolubility of full-length WT1 protein, the zinc finger do-
(CBP) or other coactivators (reviewed in Montminy, mains of WT1(2KTS) and WT1(1KTS) were cloned into the pGEX3X
GST-expression vector (Pharmacia) and expressed in Escherichia1997). Defining the contribution of this site to the regula-
coli BL21. For mutational analysis of the WT1-binding site, oligonu-tion of amphiregulin by WT1 will require the identification
cleotides containing single base pair substitutions within the WREof the specific CREB family members that target the
were annealed, subcloned, and verified by nucleotide sequencing.
CRE site and their functional interaction with WT1. End-labeled probes (20,000 cpm) were incubated with 200 ng of
The identification of amphiregulin as an in vivo target GST-WT1 protein in binding buffer (50 mM HEPES [pH 7.4], 50 mM
gene for WT1 allows a reevaluation of its characteriza- KCl, 50 mM ZnSO4, 5 mM MgCl2, 1 mM dithiothreitol, 20% glycerol,
and 1 mg of poly[dI-dC]:poly[dI-dC]). After incubation for 30 min attion as a transcriptional repressor. In this respect, the
48C, binding reactions were electrophoresed on a 5% polyacryl-properties of WT1 bear some similarity with those of p53,
amide gel in 0.53 TBE buffer for 2 hr at 180 V. For competitionwhich represses numerous target promoters in reporter
experiments, excess unlabeled annealed oligonucleotides wereassays, but whose biological functions are more clearly
added to 100 ng of GST-WT1 in binding buffer. Competitor DNA
linked to transcriptional activation of specific targets was incubated for 10 min at room temperature prior to addition of
(Seto et al., 1992; El-Deiry et al., 1993). In addition to its labeled probe, followed by incubation for an additional 20 min at 48C.
indirect activation of the MIS promoter (Nachtigal et al.,
1998), WT1 has recently been shown to activate Dax1, Footprinting Analysis
another gene implicated in gonadal differentiation (Kim An XhoI/SacI DNA fragment containing nucleotides 2385 to 287 of
the human amphiregulin promoter was end labeled using Klenow,et al., 1999). The tumor suppressor properties of WT1
and gel-purified probe (20,000 cpm) was incubated with 0, 20, oralso appear to be more closely linked to transcriptional
80 ml of GST-WT1 in binding buffer (100 mM KCl, 50 mM HEPESactivation than repression. A Wilms tumor±derived point
[pH 7.4], 10 mM ZnSO4, 5 mM MgCl2, 1 mM DTT, 6% glycerol, andmutation that abrogates the growth inhibitory effect of 2 mg poly[dI-dC]:poly[dI-dC]) for 30 min at room temperature. Bind-
WT1 demonstrates impaired transcriptional activation ing reactions were treated with DNase I in total reaction volume
of a promoter reporter but unaltered repression of a GC- of 120 ml, and the digestion was terminated after 30 s with an equal
volume of stop solution (40 mM EDTA, 2 M ammonium acetate, 5rich promoter (English and Licht, 1999). Similarly, the
Cell
672
mg tRNA). DNA fragments were ethanol precipitated and separated D.A. (1997). Induction of p21 by the Wilms' tumor suppressor gene
WT1. Cancer Res. 57, 1429±1434.by electrophoresis on a 6% sequencing gel in 13 TBE buffer. The
sequence of the protected region was determined by alignment with English, M.A., and Licht, J.D. (1999). Tumor-associated WT1 mis-
an end-labeled A1G ladder. sense mutants indicate that transcriptional activation by WT1 is
critical for growth control. J. Biol. Chem. 274, 13258±13263.
RNA In Situ Hybridization and Immunohistochemistry Fisher, D.A., Salido, E.C., and Barajas, L. (1989). Epidermal growth
Riboprobes of 250 bp were generated from the 39 coding region of factor and the kidney. Annu. Rev. Physiol. 51, 67±80.
human amphiregulin and the 39 UTR of WT1 and subcloned in
Haber, D.A., Sohn, P.L., Buckler, A.J., Pelletier, J., Call, K.M., andpSPT18 (Boehringer Mannheim). Sense and antisense probes were
Housman, D.E. (1991). Alternative splicing and genomic structuresynthesized and labeled with digoxigenin-UTP (Boehringer Mann-
of the Wilms tumor gene WT1. Proc. Natl. Acad. Sci. USA 88, 9618±heim). Signal amplification was accomplished using the TSA-Indi-
9622.rect Kit according to the manufacturer's recommendations (NEN
Haber, D.A., Park, S., Maheswaran, S., Englert, C., Re, G.G., Hazen-Life Science Products) using anti-digoxigenin antibody (1:200). Im-
Martin, D.J., Sens, D.A., and Garvin, A.J. (1993). WT1-mediatedmunohistochemistry was performed on formalin-fixed, paraffin-
growth suppression of Wilms tumor cells expressing a WT1 splicingembedded tissue sections using avidin-biotin-peroxidase as de-
variant. Science 262, 2057±2059.scribed (Hsu et al., 1981). Pretreatment was microwave heating for
5 min in 0.01 M citric acid buffer (pH 6). Antibodies WT1 (C19) (Santa Harkin, D.P., Bean, J.M., Miklos, D., Song, Y.-H., Truong, V.B., Eng-
Cruz, Santa Cruz, CA) at a dilution of 1:4 and Amphiregulin Ab-1 lert, C., Christians, F.C., Ellisen, L.W., Maheswaran, S., Oliner, J.D.,
(Neomarkers, Inc., Fremont, CA) at a dilution of 1:50 were used. and Haber, D.A. (1999). Induction of GADD45 and JNK/SAPK-depen-
Negative control sections substituted normal rabbit serum for the dent apoptosis following inducible expression of BRCA1. Cell 97,
primary antibody. 575±586.
Hastie, N.D. (1994). The genetics of Wilms' tumorÐa case of dis-
In Vitro Kidney Culture rupted development. Annu. Rev. Genet. 28, 523±558.
Metanephric kidney rudiments were isolated from gestation day Hsu, S.M., Raine, L., and Fanger, H. (1981). Use of avidin-biotin-
11.5 mouse embryos. The morphology of the ureteric bud was exam- peroxidase complex (ABC) in immunoperoxidase techniques: a
ined in fresh isolates by stereomicroscopy; rudiments with a single comparison between ABC and unlabeled antibody (PAP) proce-
ureteric bud tubule and blunt, dilated ampulla were selected for dures. J. Histochem. Cytochem. 29, 577±580.
culture. Rudiments were placed on nitrocellulose filters (0.3 mm pore
Iyer, V.R., Eisen, M.B., Ross, D.T., Schuler, G., Moore, T., Lee, J.C.,size; Costar Transwell) suspended over DMEM/10% FCS or DMEM/
Trent, J.M., Staudt, L.M., Hudson, J., Jr., Boguski, M.S., et al. (1999).10% FCS containing various concentrations of recombinant Amphi-
The transcriptional program in the response of human fibroblastsregulin (R&D Systems). Samples were cultured at the air/medium
to serum. Science 283, 83±87.
interface for 72 hr at 378C with 5% CO2, fixed and stained with FITC-
Kadonaga, J. (1998). Eukaryotic transcription: an interlaced networkDolichos Bifloris to visualize the branching ureteric bud network
of transcription factors and chromatin-modifying machines. Cell 92,(Qiao et al., 1999), and analyzed for the number of terminal ureteric
307±313.bud branches.
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